GH Research PLC (GHRS)Healthcare | Biotechnology | Dublin, Ireland | NasdaqGM
27.94 USD
-0.71
(-2.478%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 28.16 +0.22 (0.787%) ⇧ (Aug. 28, 2026, 7:52 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:53 a.m. EDT
The fundamental picture is mixed but leans negative due to the lack of profitability and negative free cash flow, despite a technically strong recovery over the last two years. The company has raised capital recently, which is a standard defensive move for biotech firms, yet the balance sheet remains fragile without earnings. While the long-term trajectory shows a net gain over four years, the recent price action is volatile, trading well above its 200-day average but failing to sustain momentum above the 50-day line. The options market is screaming caution; the heavy put positioning at lower strikes suggests a fear of a sharp correction, while the call buying is speculative and distant. With no dividend to cushion the blow and negative earnings, this is a high-risk speculative play rather than a core investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.186229 |
| AutoARIMA | 0.310678 |
| AutoETS | 0.321779 |
| MSTL | 0.344287 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 1.05 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.105 |
| Excess Kurtosis | -0.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.1 |
| Market Cap | 1,917,865,600 |
| Forward P/E | -15.10 |
| Beta | 1.29 |
| Website | https://www.ghres.com |
As of Aug. 22, 2026, 5:53 a.m. EDT: Speculators are positioning for a significant downside gap, evidenced by massive open interest in October 2026 puts at the $20 strike compared to negligible call volume. Conversely, call buyers are focused on the $35 and $40 strikes, creating a distinct 'gap' in the middle where the current price sits, suggesting a binary outcome expectation rather than a linear rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0567122 |
| Address1 | Joshua Dawson House |
| Address2 | Dawson Street |
| All Time High | 31.439 |
| All Time Low | 5.05 |
| Ask | 36.6 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 182,050 |
| Average Daily Volume3 Month | 290,316 |
| Average Volume | 290,316 |
| Average Volume10Days | 182,050 |
| Beta | 1.29 |
| Bid | 20.99 |
| Bid Size | 2 |
| Book Value | 5.237 |
| City | Dublin |
| Country | Ireland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 27.94 |
| Current Ratio | 28.696 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 28.61 |
| Day Low | 27.85 |
| Debt To Equity | 0.1 |
| Display Name | GH Research |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -71,329,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -21.808 |
| Enterprise Value | 1,555,575,552 |
| Eps Current Year | -1.17444 |
| Eps Forward | -1.85 |
| Eps Trailing Twelve Months | -0.96 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 27.6339 |
| Fifty Day Average Change | 0.30610085 |
| Fifty Day Average Change Percent | 0.011077005 |
| Fifty Two Week Change Percent | 105.67122 |
| Fifty Two Week High | 31.439 |
| Fifty Two Week High Change | -3.4989986 |
| Fifty Two Week High Change Percent | -0.11129485 |
| Fifty Two Week Low | 11.83 |
| Fifty Two Week Low Change | 16.11 |
| Fifty Two Week Low Change Percent | 1.3617921 |
| Fifty Two Week Range | 11.83 - 31.439 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,627,800,000 |
| Float Shares | 32,371,703 |
| Forward Eps | -1.85 |
| Forward P E | -15.102703 |
| Free Cashflow | -36,524,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 73 |
| Fullday Change | -0.709999 |
| Fullday Change Percent | -2.47818 |
| Fullday Price | 28.16 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.24195999 |
| Held Percent Institutions | 0.75357 |
| Implied Shares Outstanding | 68,642,287 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-25 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. |
| Long Name | GH Research PLC |
| Market | us_market |
| Market Cap | 1,917,865,600 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_707594028 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -62,270,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,967,287,945 |
| Number Of Analyst Opinions | 9 |
| Open | 28.61 |
| Operating Cashflow | -51,703,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 353 1 437 8334 |
| Post Market Change | 0.21999931 |
| Post Market Change Percent | 0.7873991 |
| Post Market Price | 28.16 |
| Post Market Time | 1,787,961,133 |
| Previous Close | 28.65 |
| Price Eps Current Year | -23.790062 |
| Price Hint | 2 |
| Price To Book | 5.3351154 |
| Profit Margins | 0.0 |
| Quick Ratio | 28.215 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.709999 |
| Regular Market Change Percent | -2.47818 |
| Regular Market Day High | 28.61 |
| Regular Market Day Low | 27.85 |
| Regular Market Day Range | 27.85 - 28.61 |
| Regular Market Open | 28.61 |
| Regular Market Previous Close | 28.65 |
| Regular Market Price | 27.94 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 117,626 |
| Return On Assets | -0.1302 |
| Return On Equity | -0.18794 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 68,642,287 |
| Shares Percent Shares Out | 0.0458 |
| Shares Short | 3,144,599 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,945,918 |
| Short Name | GH Research PLC |
| Short Percent Of Float | 0.1169 |
| Short Ratio | 8.39 |
| Source Interval | 15 |
| Symbol | GHRS |
| Target High Price | 65.0 |
| Target Low Price | 38.0 |
| Target Mean Price | 42.88889 |
| Target Median Price | 40.0 |
| Total Cash | 362,649,984 |
| Total Cash Per Share | 5.283 |
| Total Debt | 360,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.96 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.422575 |
| Two Hundred Day Average Change | 8.517426 |
| Two Hundred Day Average Change Percent | 0.43853226 |
| Type Disp | Equity |
| Volume | 117,626 |
| Website | https://www.ghres.com |
| Zip | D02 RY95 |